CC-10004 Celgene

Current Opinion in Investigational Drugs

Volumn 6, Issue 5, 2005, Pages 518-525

  Khobzaoui, Moussa ^a   Gutke, Hans Jürgen ^a   Burnet, Michael ^a  

^a Synovo GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CATECHOL DERIVATIVE; CC 10004; CILOMILAST; ETANERCEPT; INDOMETACIN; INTERLEUKIN 10; ISOINDOLE DERIVATIVE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ZARDAVERINE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYTOKINE; PHOSPHODIESTERASE INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRITIS; BACKACHE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIZZINESS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EXPOSURE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY SKIN; ENZYME INHIBITION; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE STRAIN; NONHUMAN; REVIEW; ANIMAL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG ANTAGONISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PSORIASIS;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ASTHMA; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHOSPHODIESTERASE INHIBITORS; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 18144409148     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 30729 Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. Marivet MC, Bourguignon JJ, Lugnier C, Mann A, Stoclet JC, Wermuth CG J MED CHEM 1989 32 7 1450-1457
2. 218883 Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, Stirling DI J MED CHEM 1996 39 17 3238-3240
3. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS et al J MED CHEM 1996 39 1 120-125
4. 276922 PDE4 inhibitors: The use of molecular cloning in the design and development of novel drugs. Hughes B, Owens R, Perry M, Warrellow G, Allen R DRUG DISCOV TODAY 1997 2 3 89-101
5. 282364 Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G J IMMUNOL 1995 155 10 4909-4916
6. 316578 SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ J PHARMACOL EXP THER 1998 287 2 705-711
7. 381233 Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milbum MV, Zhao Y, Ke H, Nolte RT SCIENCE 2000 288 5472 1822-1825
8. 3H]rolipram binding. Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinskii LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ BIOCHEM PHARMACOL 1996 51 7 949-956
9. 402539 Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Hatzelmann A, Schudt C J PHARMACOL EXP THER 2001 297 1 267-279
10. 412899 In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. Bunduschuh DS, Eltze M, Barsig J, Wollin L, Hatzemann A, Beume R J PHARMACOL EXP THER 2001 297 1 280-290
11. 417412 Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues. Van der May M, Hatzelmann A, Van der Laan IJ, Stork GJ, Thibaut U, Timmerman H J MED CHEM 2001 44 16 2511-2522
12. 417497 Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexahydrophthalazinones. Van der Mey M, Hatzelmann A, Van Klink GP, Van der Laan IJ, Sterk GJ, Thibaut U, Ulrich WR, Timmerman H J MED CHEM 2001 44 16 2523-2535
13. 480517 Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Burnouf C, Pruniaux MP CURR PHARM DES 2002 8 14 1255-1296
14. 488687 Asthma Therapeutics - SMi Conference, London, UK. Lunec A IDDB MEETING REPORT 2003 April 31 - May 01
15. 497891 The effects of thalidomide analogues on VEGF and IL-6 production in myeloma and endothelial cell cocultures. Molostvov G, Morris A, Rose P, Basu S J THROMB HEMOST 2003 1 Suppl 1 Abs P1226
16. 509655 Novel anti-inflammatory compounds based on the biology of thalidomide; Small molecule, oral TNFα inhibitors. Stirling D SMI CONF - ANTIINFLAMM THER 2003 October 15-16
17. 513310 Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: Structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gone potassium channel binding affinity. Friesen RW, Ducharme Y, Ball RG, Blouin M, Boulet L, Cote B, Frenette R, Girard M, Guay D, Huang Z, Jones TR et al J MED CHEM 2003 46 12 2413-2426.
18. 527734 CC-10004: A novel PDE4 inhibitor with an improved therapeutic index. Schafer P SMI CONF CHRON OBSTRUCT PULM DISORDERS 2004 March 10-11
19. 531072 A trivalent bispecific fusion protein engineered from antibody variable domains for improved pretargeting of CEA-expressing cancers. Edmund A, Rossi SK, Saha RM, Sharkey HK, Horak ID, Goldenberg DM, Chang CH PROC AM ASSOC CANCER RES 2004 95 Abs 1019
20. 535903 Novel anti-angiogenic agents; mutiple shots on goal. Stirling D SMI CONF ANTI-ARTHRITIC AGENTS April 2004
21. 550323 Celgene Corporation reports record operating performance in second quarter with strong revenue and profit growth. Celgene Corp PRESS RELEASE 2004 July 22
22. 550581 In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole -3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C J PHARMACOL EXP THER 2003 307 1 373-385
23. 550583 Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1- (4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. Draheim R, Egerland U, Rundfeldt C J PHARMACOL EXP THER 2004 308 2 555-563
24. 580212 The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. Molostvov G, Morris A, Rose P, Basu S, Muller G BR J HAEMATOL 2004 124 3 366-375
25. 583746 Structural basis for the activity of drugs that inhibit phosphodiesterases. Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR et al STRUCTURE 2004 12 12 2233-2247
26. 583773 Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lipworth BJ LANCET 2005 365 9454 167-175
27. 587262 Anti-Arthritis Therapies 2005, London, UK. Braddock M IDDB MEETING REPORT 2005 February 23-24
28. 587324 Celgene Corp company profile from company website. Celgene Corp COMPANY WORLD WIDE WEB SITE 2004 October 22
29. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. Robichaud A, Stamatiou PB, An SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC J CLIN INVEST 2002 110 7 1045-1052
30. 588333 Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869. No authors listed DRUGS R D 2004 5 3 176-181
31. 588335 Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes. Denis D, Riendeau D EUR J PHARMACOL 1999 367 2-3 343-350
32. 590470 Crystal structure of phosphodiesterase 4D and inhibitor complex 1. Lee ME, Markowitz J, Lee JO, Lee H FEBS LETT 2002 530 1-3 53-58
33. 591068 Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Huai Q, Wang H, Sun Y, Kim HY, Liu Y, Ke H STRUCTURE 2003 11 7 865-873
34. 591100 Analogues of 4-(3,4-dimethoxybenzyl)-2-imidazolidinone as potent inhibitors of rat erythrocyte adenosine cyclic 3′,5′-phosphate phosphodiesterase. Sheppard H, Wiggan G MOL PHARMACOL 1971 7 1 111-115
35. 592024 The potential of PDE4 inhibitors in respiratory disease. Spina D CURR DRUG TARGETS INFLAMM ALLERGY 2004 3 3 231-236
36. 592298 Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors. Oger S, Mehats C, Barnette MS, Ferre F, Cabrol D, Leroy MJ BIOL REPROD 2004 70 2 458-464
37. 592299 The rebirth of a drug: Thaildomide. Lima LM, Fraga CAM, Barreiro EJ QUÍM NOVA 2001 24 5 683-688.
38. 592494 Searching for a reliable orientation of ligands in their binding site: Comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors. Gratteri P, Bonaccini C, Melani F J MED CHEM 2005 48 5 1657-1665
39. 592659 Case study: CC-10004, novel anti-arthritic agents. Bennet B B2B CONF - ANTI-ARTHRITIS THERAPIES 2005 February 24-25